on 05-01-201210:35 AM - edited on 10-15-202105:29 AM by Closed Account
July 22, 2009
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the introduction of a drug screening and confirmation solution for forensic toxicology based on its Thermo Scientific Exactive benchtop LC/MS (liquid chromatography-mass spectrometry) platform. The solution incorporates the ultrahigh resolution LC/MS capabilities of the company's proprietary Orbitrap technology. Expected to become an industry standard for ease of use and performance in routine labs, this new Thermo Scientific solution will be showcased at booth 2815 at the American Association for Clinical Chemistry (AACC) 2009 exhibition, being held in Chicago from July 21 - 23.
The new system expands the current clinical research portfolio of Thermo Fisher's triple-stage quadrupole and ion trap LC/MS solutions, which includes quantitative methodologies for analyzing vitamin D, immunosuppressants, testosterone, opiates, benzodiazepines, THC, peptides and other endogenous compounds.
This new solution delivers a strong return on investment by dramatically improving ease of use and increasing sample throughput, all while providing high-confidence results. It includes the Thermo Scientific Transcend TLX UHPLC-based multiplexing system with patented TurboFlow™ technology for online sample extraction, and integrates Thermo Scientific ToxID software and reagents.
"What distinguishes this Thermo Scientific solution from competing products is the exceptionally high performance and ease of use at an affordable price," said Jeff Zonderman, director, Thermo Fisher Scientific life science mass spectrometry clinical and toxicology markets. "We have taken high-end technology previously used only in research and created a solution for the novice."